How Much More Can Boston Scientific Stock Move After Losing Half Its Value?

Options price a band whose floor sits below anything the stock has touched in the past year, and the company’s own recovery timetable lands after that window closes.

Boston Scientific (BSX) (NYSE: BSX) trades near $51.42, about half what it fetched a year ago while the S&P 500 rose about 23%. A decline that deep is usually taken to mean the risk has come out of the price. The options chain says otherwise: it prices a 68% chance the stock finishes between $35 and $77.42 over the next ten months. That width is not vague nervousness about a fallen stock: the company’s own repair timetable runs past the window the options are pricing.

The Priced Floor Sits Under A Low The Stock Has Already Hit

The ceiling at $77.42 sits about $26 above today’s price; the floor at $35 is about $16.42 below it, under the $42.63 low the stock printed over the past twelve months. Implied volatility prices the size of a move, not its direction; neither end is a forecast. Even the priced ceiling leaves the stock far short of the $108.14 it traded at within the past year.

Options Cost More Than This Stock’s Own Record Of Moving

At-the-money implied volatility of 44.4% runs at 1.22 times the 36.5% the stock has actually delivered over the trailing year. Implied volatility above realized volatility is the options market pricing more than business as usual, and it is charging that premium on a stock that has already halved.

Two Franchises Slowed At Once, And Neither Slowdown Looks Cyclical

Management’s guidance reduction is concentrated in two businesses. Demand for its Watchman heart device slowed sharply in the U.S. as accumulating clinical evidence changed which patients get referred. The company’s own FARAPULSE platform pushed electrophysiology to PFA faster than it expected, and competitive share movement in the U.S. has run beyond what it anticipated; with PFA at about 80% of the U.S. atrial fibrillation market on its own estimate, there is little conversion left to absorb the share it is losing.

Neither is a cycle waiting to turn: management is not assuming Watchman improves in 2027, and it says that level of conversion limits its ability to offset competitive pressure. The rest of the business, roughly 75% of revenue, is still expected to grow about 6% in the second half of 2026: a two-franchise problem, not a broken company, though management expects limited adjusted EPS growth in 2027. Growth that keeps working while headline franchises stall is one of the qualities the Trefis High Quality Portfolio looks for in its holdings.

The Repairs Land After The Option Window Closes

Nothing that repairs either franchise lands inside the ten months the options are pricing. The catalysts are dated later: seven launches arrive in 2028, into markets management sizes at more than $25 billion. A restructuring program targets about $500 million of run-rate savings exiting 2029, over half of it expected exiting 2027. The Penumbra deal, expected to close in the second half of 2026, lands inside that window. A question that cannot resolve before the options expire is exactly what a wide band prices. Size the position to the band rather than to the recovery, and check how much range the options market prices into other large-cap names first.

A Band This Wide Is A Lot To Carry In One Name

Boston Scientific may well finish the ten months comfortably inside the priced band. The catch is that a single holding hands you the entire range while the fix stays dated past the window. A rules-based basket of quality businesses spreads that same risk across names whose growth is not waiting on one timetable. That portfolio has a track record of outpacing the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.